Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumab

Cancer Immunol Immunother. 2017 Oct;66(10):1377-1378. doi: 10.1007/s00262-017-2012-0. Epub 2017 May 11.

Authors

Markus V Heppt¹, Ilana Goldscheider¹, Julia K Tietze¹, Carola Berking²

Affiliations

¹ Department of Dermatology and Allergy, Munich University Hospital (LMU), Frauenlobstr. 9-11, 80337, Munich, Germany.
² Department of Dermatology and Allergy, Munich University Hospital (LMU), Frauenlobstr. 9-11, 80337, Munich, Germany. Carola.Berking@med.uni-muenchen.de.

No abstract available

Keywords: Cutaneous Melanoma; Immune Checkpoint; Immune Checkpoint Blockade; Mucosal Melanoma; Oncolytic Virus.

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / administration & dosage
Antineoplastic Agents, Immunological / pharmacology
Drug Resistance, Neoplasm / drug effects*
Humans
Injections, Intralesional
Interleukin-2 / administration & dosage*
Male
Melanoma / drug therapy*
Melanoma / pathology
Mouth Mucosa / drug effects*
Mouth Mucosa / pathology
Nivolumab / pharmacology*
Prognosis

Substances

Antineoplastic Agents
Antineoplastic Agents, Immunological
Interleukin-2
Nivolumab